,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2016', 'fs': 'Apr 2016', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY1s2AH'}, 'Id': 'a0POZ00000CNY1s2AH', 'Event_Date__c': '2016-04-20', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Apr 2016', 'Status_History__c': 'a132P000000Ar6pQAC'}, 'change': None}]",Apr 2016,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Committee noted that there was an ongoing randomised controlled trial (the FORDMD study) comparing prednisone with deflazacort in boys with confirmed DMD, with planned follow-up of between 3 to 6 years. The Committee requested that this trial be brought to the Committee for review once it was published.', 'fs': 'The Committee noted that there was an ongoing randomised controlled trial (the FORDMD study) comparing prednisone with deflazacort in boys with confirmed DMD, with planned follow-up of between 3 to 6 years. The Committee requested that this trial be brought to the Committee for review once it was published.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2016', 'fs': 'Aug 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY1t2AH'}, 'Id': 'a0POZ00000CNY1t2AH', 'Event_Date__c': '2016-08-11', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 11 August 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Committee noted that there was an ongoing randomised controlled trial (the FORDMD study) comparing prednisone with deflazacort in boys with confirmed DMD, with planned follow-up of between 3 to 6 years. The Committee requested that this trial be brought to the Committee for review once it was published.', 'Formatted_Date__c': 'Aug 2016', 'Status_History__c': 'a132P000000ArAhQAK'}, 'change': None}, {'Summary': {'s': 'The Subcommittee recommended that PTAC review its recommendation for deflazacort for DMD based on the Subcommittee&#39;s review of PTAC&#39;s minutes.', 'fs': 'The Subcommittee recommended that PTAC review its recommendation for deflazacort for DMD based on the Subcommittee&#39;s review of PTAC&#39;s minutes.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2016-11.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2016-11.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Neurological Subcommittee at meeting Monday 7 November 2016.', 'fs': 'Clinical advice received from Neurological Subcommittee at meeting Monday 7 November 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY1v2AH'}, 'Id': 'a0POZ00000CNY1v2AH', 'Event_Date__c': '2016-11-07', 'Event_Description__c': 'Clinical advice received from Neurological Subcommittee at meeting Monday 7 November 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-neurological-subcommittee-minutes-2016-11.pdf"" target=""_blank"">Neurological Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Summary__c': 'The Subcommittee recommended that PTAC review its recommendation for deflazacort for DMD based on the Subcommittee&#39;s review of PTAC&#39;s minutes.', 'Formatted_Date__c': 'Nov 2016', 'Status_History__c': 'a132P000000ArDWQA0'}, 'change': None}, {'Summary': {'s': 'The Committee reiterated that it would like to review its recommendation once the FOR-DMD study was published.', 'fs': 'The Committee reiterated that it would like to review its recommendation once the FOR-DMD study was published.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2017', 'fs': 'Feb 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 February 2017.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 February 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY1x2AH'}, 'Id': 'a0POZ00000CNY1x2AH', 'Event_Date__c': '2017-02-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 February 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Committee reiterated that it would like to review its recommendation once the FOR-DMD study was published.', 'Formatted_Date__c': 'Feb 2017', 'Status_History__c': 'a132P000000ArFdQAK'}, 'change': None}, {'Summary': {'s': 'The Committee considered correspondence from Muscular Dystrophy New Zealand (MDNZ) requesting that consideration be given to a post hoc analysis of the Ataluren Confirmatory Trial (ACT) DMD study (Shieh et al. Muscle Nerve 2018;58:639-45) that had recently been published. The Committee thanked MDNZ for providing this for review. The Committee considered that this trial provided retrospective data (Shieh et al. Muscle Nerve 2018;58:639- 10-45) and that the evidence did not change the Committee&#39;s recommendation for decline. The Committee reiterated that it would like to review its recommendation once the FOR-DMD study (ClinicalTrials.gov Identifier: NCT01603407) was published; noting that this is a randomised controlled trial.', 'fs': 'The Committee considered correspondence from Muscular Dystrophy New Zealand (MDNZ) requesting that consideration be given to a post hoc analysis of the Ataluren Confirmatory Trial (ACT) DMD study (Shieh et al. Muscle Nerve 2018;58:639-45) that had recently been published. The Committee thanked MDNZ for providing this for review. The Committee considered that this trial provided retrospective data (Shieh et al. Muscle Nerve 2018;58:639- 10-45) and that the evidence did not change the Committee&#39;s recommendation for decline. The Committee reiterated that it would like to review its recommendation once the FOR-DMD study (ClinicalTrials.gov Identifier: NCT01603407) was published; noting that this is a randomised controlled trial.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2019', 'fs': 'Feb 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY1y2AH'}, 'Id': 'a0POZ00000CNY1y2AH', 'Event_Date__c': '2019-02-21', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 21 February 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2019-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Committee considered correspondence from Muscular Dystrophy New Zealand (MDNZ) requesting that consideration be given to a post hoc analysis of the Ataluren Confirmatory Trial (ACT) DMD study (Shieh et al. Muscle Nerve 2018;58:639-45) that had recently been published. The Committee thanked MDNZ for providing this for review. The Committee considered that this trial provided retrospective data (Shieh et al. Muscle Nerve 2018;58:639- 10-45) and that the evidence did not change the Committee&#39;s recommendation for decline. The Committee reiterated that it would like to review its recommendation once the FOR-DMD study (ClinicalTrials.gov Identifier: NCT01603407) was published; noting that this is a randomised controlled trial.', 'Formatted_Date__c': 'Feb 2019', 'Status_History__c': 'a132P000000ArbXQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY1z2AH'}, 'Id': 'a0POZ00000CNY1z2AH', 'Event_Date__c': '2023-12-12', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004VA0nYAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2024', 'fs': 'Apr 2024', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 16 May 2024', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 16 May 2024', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY202AH'}, 'Id': 'a0POZ00000CNY202AH', 'Event_Date__c': '2024-04-19', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Thursday 16 May 2024', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Apr 2024', 'Status_History__c': 'a13OZ00000A1IZsYAN'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Advisory Committee <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pujy/p001458"" target=""_blank"">reaffirmed its previous recommendation</a> that the application for deflazacort for DMD be <strong>declined</strong>.</p><p>\xa0</p><p><a href=""https://pharmac.govt.nz/assets/2024-05-PTAC-meeting-record.pdf#page=15"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'fs': '<p>The Advisory Committee <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pujy/p001458"" target=""_blank"">reaffirmed its previous recommendation</a> that the application for deflazacort for DMD be <strong>declined</strong>.</p><p>\xa0</p><p><a href=""https://pharmac.govt.nz/assets/2024-05-PTAC-meeting-record.pdf#page=15"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2024-05-PTAC-meeting-record.pdf"" target=""_blank"">Link to the meeting record.</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2024-05-PTAC-meeting-record.pdf"" target=""_blank"">Link to the meeting record.</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2024', 'fs': 'Aug 2024', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 16 May 2024.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 16 May 2024.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY212AH'}, 'Id': 'a0POZ00000CNY212AH', 'Event_Date__c': '2024-08-13', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 16 May 2024.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2024-05-PTAC-meeting-record.pdf"" target=""_blank"">Link to the meeting record.</a></p>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Aug 2024', 'Published_Recommendation__c': '<p>The Advisory Committee <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008pujy/p001458"" target=""_blank"">reaffirmed its previous recommendation</a> that the application for deflazacort for DMD be <strong>declined</strong>.</p><p>\xa0</p><p><a href=""https://pharmac.govt.nz/assets/2024-05-PTAC-meeting-record.pdf#page=15"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'Status_History__c': 'a13OZ00000DE00oYAD'}, 'change': None}]",Aug 2016,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2016', 'fs': 'Aug 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY1u2AH'}, 'Id': 'a0POZ00000CNY1u2AH', 'Event_Date__c': '2016-08-11', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Aug 2016', 'Status_History__c': 'a132P000000ArAnQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY222AH'}, 'Id': 'a0POZ00000CNY222AH', 'Event_Date__c': '2024-09-04', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000DvcNeYAJ'}, 'change': None}]",Aug 2016,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY1w2AH'}, 'Id': 'a0POZ00000CNY1w2AH', 'Event_Date__c': '2016-11-30', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2016', 'Status_History__c': 'a132P000000ArEEQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CNY232AH'}, 'Id': 'a0POZ00000CNY232AH', 'Event_Date__c': '2024-09-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000E40wAYAR'}, 'change': None}]",Nov 2016,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
